An Open-label, Randomized, Four-way Cross-over, Single Oral Dose Study Comparing the Pharmacokinetics of Four Different Formulations of AZD9977 (Part A) and Influence of Food (Part B) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2018
At a glance
- Drugs AZD 9977 (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 05 Apr 2018 Status changed from not yet recruiting to recruiting.
- 05 Apr 2018 Planned End Date changed from 8 Jun 2018 to 6 Jun 2018.
- 05 Apr 2018 Planned primary completion date changed from 8 Jun 2018 to 6 Jun 2018.